Advanced searches left 3/3

Sunitinib - BioProject

Summarized by Plex Scholar
Last Updated: 18 February 2022

* If you want to update the article please login/register

miRNA array of clear cell renal cell carcinoma from patients treated with sunitinib

Sunitinib, a multiple receptor tyrosine kinase inhibitor, is the first-line treatment for clear cell renal cell carcinoma. Sunitinib resistance Here we analyzed a microRNA and its target. MiR-96-5p upregulation in tumors from sunitinib-resistant CCRCC patients was found in miR-96-5p tumors from sunitinib-resistant CCRCC patients' blood cell transplantation. Overall idea: We performed global miRNA profiling using frozen tissues from CCRCC tumors and adjacent noncancerous kidney tissue of six patients who received sunitinib therapy, according to the sunitinib-resistant kidney tissue of six patients with RNA-treated.

Source link: https://www.ncbi.nlm.nih.gov/bioproject/782565

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions